Whether you choose morning or evening injection, PlexusDx supports your preferred schedule and works with you to optimize dosing based on your response and tolerance
The same way we manage risk with psychiatric medications that have serious potential side effects
Semaglutide 2.4 mg, the active ingredient in Wegovy, produced a mean body weight reduction of 14.9% versus 2.4% with placebo over 68 weeks in the STEP-1 trial (N=1,961) [1]
Wegovy, meanwhile, can lead to a 15% weight reduction at the 2.4 mg maintenance dose after 68 weeks
What This Industry Analysis Framework Examines: For individuals evaluating GLP-1 telehealth options, the factors examined in this analysis include: Pricing transparency: Whether platforms clearly disclose costs, what's included, and cancellation terms
What are the potential side effects, and who may benefit most from this treatment